Your browser doesn't support javascript.
loading
Room for improvement: One third of Lynch syndrome patients presenting for genetic testing in a highly specialised centre in Stockholm already have cancer.
Bernstedt, Sophie Walton; Björk, Jan; Fritzell, Kaisa; Spigelman, Allan D; Björck, Erik; Backman, Ann-Sofie.
Afiliação
  • Bernstedt SW; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Björk J; Division of Gastroenterology, Medical Unit Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Fritzell K; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Spigelman AD; Division of Gastroenterology, Medical Unit Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Björck E; Patient flow Hereditary Cancer, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.
  • Backman AS; Patient flow Hereditary Cancer, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.
Hered Cancer Clin Pract ; 19(1): 18, 2021 Feb 12.
Article em En | MEDLINE | ID: mdl-33579353
BACKGROUND: Lynch syndrome is caused by germline mutations in the mismatch repair genes and is characterised by a familial accumulation of colorectal and other cancers. Earlier identification of Lynch syndrome patients enables surveillance and might reduce the risk of cancer. It is important to explore whether today's clinical care discovers patients with Lynch syndrome suitable for surveillance in time. This study aimed to describe what led to a diagnosis of Lynch syndrome in the cohort referred to the Hereditary Gastrointestinal Cancer Unit, Karolinska University Hospital, Solna, Sweden for gastrointestinal surveillance. METHODS: This was a descriptive study. Data from 1975 to 2018 were collected and compiled as a database. Age at diagnosis was calculated from the date when a pathogenic MMR gene mutation was confirmed, from the period June 1994-September 2018. Data were collected from patient protocols prospectively during patient consultations and medical records retrospectively. Criteria for inclusion were registration at the outpatient clinic and a confirmed mismatch repair gene mutation. RESULTS: A total of 305 patients were eligible for inclusion. Three major reasons for diagnosis were identified: 1. Predictive testing of a previously known mutation in the family (62%, mean age 37), 2. A family history of Lynch associated tumours (9%, mean age 37), 3. A diagnosis of cancer (29%, mean age 51). The proportion diagnosed due to cancer has not changed over time. CONCLUSION: A high proportion of patients (29%) were identified with Lynch syndrome after they had been diagnosed with an associated cancer, which suggests that there is significant room for improvement in the diagnosis of patients with Lynch syndrome before cancer develops.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Hered Cancer Clin Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Hered Cancer Clin Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia